Developer docs
API playgroundTry for free, no card

Search company profiles

Anixa Biosciences

Full company profile

uuid0002g1j

Namestring
Anixa Biosciences
Legal namestring
Anixa Biosciences, Inc.
Websiteurl
anixa.com
Company typeenum
Public
Founded yearint
1982
Descriptiontext

Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company developing immunotherapies for the treatment and prevention of cancer. Originally incorporated in Delaware in 1982 as ITUS Corporation and taken public in 1983, the company rebranded and pivoted to biotechnology in the early 2020s, with headquarters in San Jose, California and a small operating team of 1–10 employees.

The company's pipeline is built around two proprietary technology platforms. The first is a 'retired protein' cancer vaccine strategy, in which the immune system is primed against proteins that are normally expressed only in restricted tissues (e.g., α-lactalbumin in lactating breast tissue and AMHR2 in premenopausal ovaries) but re-emerge in malignancies. Lead programs include a breast cancer vaccine targeting α-lactalbumin — which completed Phase 1 with a 74% immune response rate across 35 participants and advanced into Phase 2 in April 2026 — and an ovarian cancer vaccine targeting AMHR2 in collaboration with Cleveland Clinic and the NCI. The second platform is Chimeric Endocrine Receptor-T cell (CER-T) therapy, an FSHR-targeted CAR-T approach using a natural FSH ligand rather than an antibody fragment; the lead asset, liraltagene autoleucel (lira-cel), is in a Phase 1 trial at Moffitt Cancer Center for recurrent, platinum-resistant ovarian cancer, with survival observations reported up to 28 months in heavily pretreated patients. Core science is licensed from Cleveland Clinic (vaccines) and the Wistar Institute (CER-T), with clinical operations conducted at Cleveland Clinic, Moffitt, Roswell Park, and the University of Chicago.

Anixa is pre-revenue and operates a capital-efficient, partnership-driven model. It licenses patented technologies from academic institutions (Cleveland Clinic, Wistar, Duke), conducts development with contract research and manufacturing organizations such as Cytovance Biologics, and intends to partner with larger pharmaceutical companies for worldwide commercialization rather than building its own sales infrastructure. Future revenue is expected to flow from licensing royalties, milestone payments, and ultimately partnered product sales across oncology indications including triple-negative breast cancer, recurrent ovarian cancer, and high-risk genetic populations (BRCA1/2, PALB2 carriers).

Short descriptiontext

Anixa Biosciences is a clinical-stage biotechnology company developing cancer immunotherapies — including a 'retired protein' breast cancer vaccine (Phase 2) and an FSHR-targeted CAR-T therapy for recurrent ovarian cancer (Phase 1) — with future commercialization planned through pharmaceutical partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelville, United States
HQ citystring
Melville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, CAR-T therapy, cancer vaccines, breast cancer treatment, ovarian cancer treatment
Industry4 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Royalties
TypeLicensing Royalties
Description

Anixa licenses its technologies from research institutions (Cleveland Clinic, Wistar Institute) and may sublicense or co-develop with larger pharmaceutical companies. Cleveland Clinic is entitled to royalties and other commercialization revenues from vaccine technologies.

anixa.com
2Milestone Payments
TypeLicensing Royalties
Description

Potential future milestone payments from pharmaceutical partnerships related to clinical development, regulatory approvals, and commercialization achievements.

anixa.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Anixa Biosciences is a clinical-stage biotechnology company developing proprietary cancer immunotherapies, including a Chimeric Endocrine Receptor-T cell (CER-T) therapy (liraltagene autoleucel) for recurrent ovarian cancer and "retired protein" vaccines targeting α-lactalbumin for breast cancer and AMHR2 for ovarian cancer. The company in-licenses technologies from leading research institutions and conducts clinical trials with the goal of partnering with pharmaceutical companies for worldwide commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 74% of participants demonstrated protocol-defined immune responses in Phase 1 breast cancer vaccine trial
+3 more records
Product overview1 text field

Anixa Biosciences is a clinical-stage biotechnology company developing a portfolio of cancer immunotherapies and vaccines. The pipeline consists of liraltagene autoleucel (lira-cel), a CAR-T/CER-T therapy for recurrent ovarian cancer in Phase 1 trials; a breast cancer vaccine targeting α-lactalbumin which completed Phase 1 and is advancing to Phase 2; an ovarian cancer vaccine targeting AMHR2; and a discovery-stage program for lung, colon, and prostate cancer vaccines. All vaccine programs use a proprietary retired-protein vaccine strategy developed in collaboration with Cleveland Clinic.

Product and service3 records
1Liraltagene Autoleucel (lira-cel)
CategoryCAR-T Cell Therapy
Description

An FSHR-targeted CAR-T (CER-T) therapy for recurrent ovarian cancer using genetically engineered patient T cells to target the follicle-stimulating hormone receptor on tumor cells. Administered via intraperitoneal route. Currently in Phase 1 clinical trial at Moffitt Cancer Center.

2Breast Cancer Vaccine
CategoryCancer Vaccine
Description

A vaccine targeting human α-lactalbumin protein for treatment and prevention of breast cancer. Based on retired-protein vaccine strategy, designed to prime the immune system against tumor cells expressing α-lactalbumin while avoiding harm to normal tissue. Completed Phase 1 with 74% immune response rate and is advancing to Phase 2.

3Ovarian Cancer Vaccine
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-01
Description

Development and manufacturing agreement with Cytovance Biologics, a full-service contract development and manufacturing organization (CDMO), to produce cGMP clinical materials for Phase 2 breast cancer vaccine trial.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cleveland Clinic is Anixa's primary strategic partner for cancer vaccine development. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and commercialization revenues. Phase 1 trials conducted at Cleveland Clinic with Dr. G. Thomas Budd and Dr. Thaddeus S. Stappenbeck as principal investigators.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Moffitt Cancer Center is Anixa's partner for ovarian cancer CAR-T therapy (lira-cel) development. The ongoing Phase 1 trial is conducted at Moffitt with Dr. Robert M. Wenham as principal investigator. Moffitt is a world leader in cancer immunotherapy including CAR-T and TILs. The technology was developed using Wistar Institute's CER-T platform.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

NCI collaborates with Anixa and Cleveland Clinic on ovarian cancer vaccine development, supporting the AMHR2-targeted immunoprevention approach.

Strategic tierCoreTypeTechnology or Integration
Description

FSHR-mediated CAR-T technology exclusively licensed to Anixa by The Wistar Institute. Dr. Jose Conejo-Garcia, co-inventor of the technology, is Professor at Duke University and previously worked at Wistar.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborator on lira-cel CAR-T therapy presentation at New York Academy of Sciences symposium, with Dr. Marco L. Davila from Department of Medicine involved in the project.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborator on lira-cel CAR-T therapy program with Dr. Richard Koya from University of Chicago involved in the project team.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborator on lira-cel CAR-T therapy with Dr. Jose Conejo-Garcia, co-inventor of FSHR-mediated CAR-T technology and Professor of Immunology, involved in the project.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Partnered with Merck on mRNA-4157 (V940), a personalized neoantigen cancer vaccine. Directly comparable to Anixa as a clinical-stage therapeutic cancer-vaccine developer, with overlapping indication strategies in oncology.

2BioNTech
TypeDirect peer
Description

Develops mRNA-based cancer vaccines, including individualized neoantigen programs for melanoma and other solid tumors. Directly comparable to Anixa as a therapeutic cancer-vaccine developer using novel biological platforms, with a similar strategic focus on oncology immunotherapy.

TypeEmerging player
Description

Develops neoantigen-based cancer vaccines (SLATE, GRANITE programs) for solid tumors including colorectal cancer. Comparable to Anixa's cancer vaccine pipeline with a similar therapeutic-vaccine mechanism but using distinct delivery platforms.

TypeDirect peer
Description

Developed Elahere (mirvetuximab soravtansine), approved for platinum-resistant ovarian cancer—the same indication as Anixa's lira-cel CAR-T. Directly comparable as a focused ovarian cancer therapy developer targeting the same underserved patient population.

TypeBroad incumbent
Description

Keytruda is approved for triple-negative breast cancer (TNBC), the lead indication for Anixa's breast cancer vaccine. Merck also partners with Moderna on the mRNA-4157 cancer vaccine. Comparable as a major oncology incumbent with overlapping indication strategy and potential partnership interest in Anixa's pipeline.

6Bristol-Myers Squibb
TypeBroad incumbent
Description

Markets multiple CAR-T therapies (Breyanzi, Abecma) and checkpoint inhibitors (Opdivo) used in ovarian cancer. Comparable as a broad oncology incumbent with an established CAR-T franchise—directly relevant to Anixa's lira-cel CAR-T program and potential acquirer profile.

TypeBroad incumbent
Description

Through Kite Pharma, markets Yescarta and Tecartus CAR-T therapies. One of the established commercial leaders in cell therapy, directly comparable to Anixa's CAR-T development effort and a logical potential commercialization partner for lira-cel.

TypeBroad incumbent
Description

Markets Kymriah, the first FDA-approved CAR-T therapy. Comparable as a broad oncology incumbent with deep CAR-T experience and a relevant acquirer/partner profile for clinical-stage CAR-T developers like Anixa.

TypeEmerging player
Description

Develops allogeneic (off-the-shelf) CAR-T therapies, including candidates in solid tumors and hematologic malignancies. Comparable as a CAR-T developer; while Anixa's lira-cel is autologous, Allogene represents the emerging competitive modality Anixa's autologous approach will be benchmarked against.

TypeBroad incumbent
Description

Markets Lynparza (PARP inhibitor for BRCA-mutated breast and ovarian cancer) and Enhertu for breast cancer, plus checkpoint inhibitor Imfinzi. Comparable as a broad oncology incumbent with overlapping indications (BRCA+ breast, ovarian cancer) and a potential partner for Anixa's breast cancer vaccine in the BRCA-mutation population.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anixa Biosciences

Cancer Immunotherapyanixa.com

Anixa Biosciences is a clinical-stage biotechnology company developing cancer immunotherapies — including a 'retired protein' breast cancer vaccine (Phase 2) and an FSHR-targeted CAR-T therapy for recurrent ovarian cancer (Phase 1) — with future commercialization planned through pharmaceutical partnerships.

What Anixa Biosciences does

Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company developing immunotherapies for the treatment and prevention of cancer. Originally incorporated in Delaware in 1982 as ITUS Corporation and taken public in 1983, the company rebranded and pivoted to biotechnology in the early 2020s, with headquarters in San Jose, California and a small operating team of 1–10 employees.

The company's pipeline is built around two proprietary technology platforms. The first is a 'retired protein' cancer vaccine strategy, in which the immune system is primed against proteins that are normally expressed only in restricted tissues (e.g., α-lactalbumin in lactating breast tissue and AMHR2 in premenopausal ovaries) but re-emerge in malignancies. Lead programs include a breast cancer vaccine targeting α-lactalbumin — which completed Phase 1 with a 74% immune response rate across 35 participants and advanced into Phase 2 in April 2026 — and an ovarian cancer vaccine targeting AMHR2 in collaboration with Cleveland Clinic and the NCI. The second platform is Chimeric Endocrine Receptor-T cell (CER-T) therapy, an FSHR-targeted CAR-T approach using a natural FSH ligand rather than an antibody fragment; the lead asset, liraltagene autoleucel (lira-cel), is in a Phase 1 trial at Moffitt Cancer Center for recurrent, platinum-resistant ovarian cancer, with survival observations reported up to 28 months in heavily pretreated patients. Core science is licensed from Cleveland Clinic (vaccines) and the Wistar Institute (CER-T), with clinical operations conducted at Cleveland Clinic, Moffitt, Roswell Park, and the University of Chicago.

Anixa is pre-revenue and operates a capital-efficient, partnership-driven model. It licenses patented technologies from academic institutions (Cleveland Clinic, Wistar, Duke), conducts development with contract research and manufacturing organizations such as Cytovance Biologics, and intends to partner with larger pharmaceutical companies for worldwide commercialization rather than building its own sales infrastructure. Future revenue is expected to flow from licensing royalties, milestone payments, and ultimately partnered product sales across oncology indications including triple-negative breast cancer, recurrent ovarian cancer, and high-risk genetic populations (BRCA1/2, PALB2 carriers).

Anixa Biosciences firmographics

Firmographics
Name
Anixa Biosciences
Legal name
Anixa Biosciences, Inc.
Website
https://anixa.com
Company type
Public
Founded year
1982
Operating status
Operating
Headcount range
11–50 employees
Short description
Anixa Biosciences is a clinical-stage biotechnology company developing cancer immunotherapies — including a 'retired protein' breast cancer vaccine (Phase 2) and an FSHR-targeted CAR-T therapy for recurrent ovarian cancer (Phase 1) — with future commercialization planned through pharmaceutical partnerships.
Ownership category
akta.pro rank

Anixa Biosciences industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Cancer immunotherapy
  • CAR-T therapy
  • Cancer vaccines
  • Breast cancer treatment
  • Ovarian cancer treatment

Where Anixa Biosciences is headquartered

Location

Headquarters

HQ city
Melville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Anixa Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Licensing and Royalties: Anixa licenses its technologies from research institutions (Cleveland Clinic, Wistar Institute) and may sublicense or co-develop with larger pharmaceutical companies. Cleveland Clinic is entitled to royalties and other commercialization revenues from vaccine technologies.
  2. Milestone Payments: Potential future milestone payments from pharmaceutical partnerships related to clinical development, regulatory approvals, and commercialization achievements.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Anixa Biosciences product offering

Product offering

Core offering

Anixa Biosciences is a clinical-stage biotechnology company developing proprietary cancer immunotherapies, including a Chimeric Endocrine Receptor-T cell (CER-T) therapy (liraltagene autoleucel) for recurrent ovarian cancer and "retired protein" vaccines targeting α-lactalbumin for breast cancer and AMHR2 for ovarian cancer. The company in-licenses technologies from leading research institutions and conducts clinical trials with the goal of partnering with pharmaceutical companies for worldwide commercialization.

Product overview

Anixa Biosciences is a clinical-stage biotechnology company developing a portfolio of cancer immunotherapies and vaccines. The pipeline consists of liraltagene autoleucel (lira-cel), a CAR-T/CER-T therapy for recurrent ovarian cancer in Phase 1 trials; a breast cancer vaccine targeting α-lactalbumin which completed Phase 1 and is advancing to Phase 2; an ovarian cancer vaccine targeting AMHR2; and a discovery-stage program for lung, colon, and prostate cancer vaccines. All vaccine programs use a proprietary retired-protein vaccine strategy developed in collaboration with Cleveland Clinic.

Differentiator

Problem solved

Functional benefit

Products and services

  • Liraltagene Autoleucel (lira-cel) An FSHR-targeted CAR-T (CER-T) therapy for recurrent ovarian cancer using genetically engineered patient T cells to target the follicle-stimulating hormone receptor on tumor cells. Administered via intraperitoneal route. Currently in Phase 1 clinical trial at Moffitt Cancer Center.
  • Breast Cancer Vaccine A vaccine targeting human α-lactalbumin protein for treatment and prevention of breast cancer. Based on retired-protein vaccine strategy, designed to prime the immune system against tumor cells expressing α-lactalbumin while avoiding harm to normal tissue. Completed Phase 1 with 74% immune response rate and is advancing to Phase 2.
  • Ovarian Cancer Vaccine

Quantifiable outcome

  • 74% of participants demonstrated protocol-defined immune responses in Phase 1 breast cancer vaccine trial
  • +3 more outcomes

Companies that use Anixa Biosciences

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Anixa Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Anixa Biosciences partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • Cytovance BiologicsminorImplementation/ SI/ Consulting Partner · 1 April 2026Development and manufacturing agreement with Cytovance Biologics, a full-service contract development and manufacturing organization (CDMO), to produce cGMP clinical materials for Phase 2 breast cancer vaccine trial.
  • Cleveland CliniccoreStrategic or Co-development PartnerCleveland Clinic is Anixa's primary strategic partner for cancer vaccine development. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and commercialization revenues. Phase 1 trials conducted at Cleveland Clinic with Dr. G. Thomas Budd and Dr. Thaddeus S. Stappenbeck as principal investigators.
  • Moffitt Cancer CentercoreStrategic or Co-development PartnerMoffitt Cancer Center is Anixa's partner for ovarian cancer CAR-T therapy (lira-cel) development. The ongoing Phase 1 trial is conducted at Moffitt with Dr. Robert M. Wenham as principal investigator. Moffitt is a world leader in cancer immunotherapy including CAR-T and TILs. The technology was developed using Wistar Institute's CER-T platform.
  • National Cancer Institute (NCI)minorStrategic or Co-development PartnerNCI collaborates with Anixa and Cleveland Clinic on ovarian cancer vaccine development, supporting the AMHR2-targeted immunoprevention approach.
  • Wistar InstitutecoreTechnology or IntegrationFSHR-mediated CAR-T technology exclusively licensed to Anixa by The Wistar Institute. Dr. Jose Conejo-Garcia, co-inventor of the technology, is Professor at Duke University and previously worked at Wistar.
  • Roswell Park Cancer CenterminorStrategic or Co-development PartnerCollaborator on lira-cel CAR-T therapy presentation at New York Academy of Sciences symposium, with Dr. Marco L. Davila from Department of Medicine involved in the project.
  • University of Chicago School of MedicineminorStrategic or Co-development PartnerCollaborator on lira-cel CAR-T therapy program with Dr. Richard Koya from University of Chicago involved in the project team.
  • Duke University Medical CenterminorStrategic or Co-development PartnerCollaborator on lira-cel CAR-T therapy with Dr. Jose Conejo-Garcia, co-inventor of FSHR-mediated CAR-T technology and Professor of Immunology, involved in the project.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Anixa Biosciences competitors and assessment

Company assessment

Direct peers

  • Moderna: Partnered with Merck on mRNA-4157 (V940), a personalized neoantigen cancer vaccine. Directly comparable to Anixa as a clinical-stage therapeutic cancer-vaccine developer, with overlapping indication strategies in oncology.
  • BioNTech: Develops mRNA-based cancer vaccines, including individualized neoantigen programs for melanoma and other solid tumors. Directly comparable to Anixa as a therapeutic cancer-vaccine developer using novel biological platforms, with a similar strategic focus on oncology immunotherapy.
  • ImmunoGen: Developed Elahere (mirvetuximab soravtansine), approved for platinum-resistant ovarian cancer—the same indication as Anixa's lira-cel CAR-T. Directly comparable as a focused ovarian cancer therapy developer targeting the same underserved patient population.

Emerging players

  • Gritstone bio: Develops neoantigen-based cancer vaccines (SLATE, GRANITE programs) for solid tumors including colorectal cancer. Comparable to Anixa's cancer vaccine pipeline with a similar therapeutic-vaccine mechanism but using distinct delivery platforms.
  • Allogene Therapeutics: Develops allogeneic (off-the-shelf) CAR-T therapies, including candidates in solid tumors and hematologic malignancies. Comparable as a CAR-T developer; while Anixa's lira-cel is autologous, Allogene represents the emerging competitive modality Anixa's autologous approach will be benchmarked against.

Broad incumbents

  • Merck & Co. Keytruda is approved for triple-negative breast cancer (TNBC), the lead indication for Anixa's breast cancer vaccine. Merck also partners with Moderna on the mRNA-4157 cancer vaccine. Comparable as a major oncology incumbent with overlapping indication strategy and potential partnership interest in Anixa's pipeline.
  • Bristol-Myers Squibb: Markets multiple CAR-T therapies (Breyanzi, Abecma) and checkpoint inhibitors (Opdivo) used in ovarian cancer. Comparable as a broad oncology incumbent with an established CAR-T franchise—directly relevant to Anixa's lira-cel CAR-T program and potential acquirer profile.
  • Gilead Sciences (Kite Pharma): Through Kite Pharma, markets Yescarta and Tecartus CAR-T therapies. One of the established commercial leaders in cell therapy, directly comparable to Anixa's CAR-T development effort and a logical potential commercialization partner for lira-cel.
  • Novartis: Markets Kymriah, the first FDA-approved CAR-T therapy. Comparable as a broad oncology incumbent with deep CAR-T experience and a relevant acquirer/partner profile for clinical-stage CAR-T developers like Anixa.
  • AstraZeneca: Markets Lynparza (PARP inhibitor for BRCA-mutated breast and ovarian cancer) and Enhertu for breast cancer, plus checkpoint inhibitor Imfinzi. Comparable as a broad oncology incumbent with overlapping indications (BRCA+ breast, ovarian cancer) and a potential partner for Anixa's breast cancer vaccine in the BRCA-mutation population.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Anixa Biosciences social profiles

Digital presence

Anixa Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anixa Biosciences leadership team

Management profile

Number of profiles

Profiles3 records

Anixa Biosciences funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anixa Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anixa Biosciences

What does Anixa Biosciences do?

Anixa Biosciences is a clinical-stage biotechnology company developing proprietary cancer immunotherapies, including a Chimeric Endocrine Receptor-T cell (CER-T) therapy (liraltagene autoleucel) for recurrent ovarian cancer and "retired protein" vaccines targeting α-lactalbumin for breast cancer and AMHR2 for ovarian cancer. The company in-licenses technologies from leading research institutions and conducts clinical trials with the goal of partnering with pharmaceutical companies for worldwide commercialization.

Is Anixa Biosciences a public or private company?

Anixa Biosciences is a public company. It is classified as public and is currently operating.

When was Anixa Biosciences founded?

Anixa Biosciences was founded in 1982. It employs 11 to 50 people.

Where is Anixa Biosciences based?

Anixa Biosciences is headquartered in Melville, United States, in the North America region.

How does Anixa Biosciences make money?

Two revenue lines are on record. Licensing and Royalties are the primary driver. The others are milestone Payments.

Who are Anixa Biosciences's main competitors?

Direct peers on record are Moderna, BioNTech and ImmunoGen. Emerging players are Gritstone bio and Allogene Therapeutics. Broad incumbents are Merck & Co., Bristol-Myers Squibb, Gilead Sciences (Kite Pharma), Novartis and AstraZeneca.

Does Anixa Biosciences have an API?

No public API is recorded for Anixa Biosciences.

What industry is Anixa Biosciences in?

Anixa Biosciences's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanAnixa Biosciences gets Canadian patent for ovarian vaccineAnixa Biosciences announced the Canadian Intellectual Property Office issued Patent 3,005,025 for its ovarian cancer vaccine technology. The patent covers methods targeting AMHR2-ED, a protein expressed in normal ovaries and certain ovarian cancers. The vaccine is part of Anixa's portfolio, which also includes a breast cancer vaccine that completed a Phase 1 trial.TradingViewAnixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine TechnologyAnixa Biosciences announced the Canadian Intellectual Property Office issued Patent 3,005,025 for its ovarian cancer vaccine technology, covering methods targeting AMHR2-ED. The patent complements Anixa's U.S. patent and strengthens international protection for the vaccine developed with Cleveland Clinic.TradingViewAnixa Biosciences, Inc. (ANIX) Receives Canadian Patent for Ovarian Cancer VaccineCanada issued Anixa Biosciences patent 3,005,025 covering its ovarian cancer vaccine technology, complementing a U.S. patent issued in July 2025. The release provides no financial terms or clinical results for the vaccine. Further clinical data or development milestones would be needed to establish a larger catalyst.Investing.comAnixa Biosciences CEO Amit Kumar buys $15,850 in company stockAnixa Biosciences CEO Amit Kumar bought 5,000 shares at $3.17 each on October 30, 2026, for $15,850. The purchase brings his direct holdings to 685,000 shares. The company also reported a stable-disease response in its Phase 1 CAR-T trial and a new patent for its breast cancer vaccine.American Banking and Market NewsAnixa Biosciences Inc (NASDAQ:ANIX) Stock Now Rated “Hold” by Wall Street BrokeragesAnixa Biosciences stock is rated 'Hold' by five brokerages, with an average 12-month price target of $8.00. The company reported a loss of $0.08 per share for the quarter, matching consensus estimates. Director Lewis Titterton bought 49,036 shares at $2.69 each.Stock TitanAnixa Biosciences to Present Ovarian CAR-T Trial at ESMOAnixa Biosciences will present its Phase 1 ovarian cancer CAR-T trial at ESMO 2026, with Dr. Robert Wenham speaking on December 14. The fifth cohort is complete with no dose-limiting toxicities, and the company plans to advance to a sixth cohort at a 1,000-fold higher dose after safety verification.MarketBeatAnixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded Anixa Biosciences from a hold to a sell rating. The stock opened at $3.12, with an average analyst rating of Hold and a target price of $8.00. The company reported a loss of $0.08 per share for the quarter, meeting consensus estimates.American Banking and Market NewsAnixa Biosciences (NASDAQ:ANIX) Stock Moved Down to “Sell” by Wall Street ZenWall Street Zen downgraded Anixa Biosciences from hold to sell on Saturday. The stock opened at $3.12, down 5.5%, with a consensus hold rating and $8.00 price target. Insiders bought 49,036 shares at $2.69, increasing their stake by 4.92%.MarketBeatAnixa Biosciences (NASDAQ:ANIX) Share Price Breaks Below 200-Day Moving Average - Time to Sell?Anixa Biosciences shares fell below their 200-day moving average on Monday, trading at $2.93 against a $2.97 average. Analysts hold a mixed view with an average rating of Hold and a $8.00 target, while insiders bought 105,536 shares in the last 90 days.MarketBeatInsider Buying: Anixa Biosciences (NASDAQ:ANIX) Director Buys 8,000 Shares of StockAnixa Biosciences director Lewis Titterton, Jr. bought 8,000 shares at $2.98 each on October 23, increasing his stake by 0.76%. The stock traded down 2% to $2.93, and analysts have a consensus 'Hold' rating with a $8.00 target.